Syngenta Selects InforSense for Workflow-Driven Bioinformatics Computational Platform
News Jan 25, 2006
InforSense Ltd. has announced that Syngenta has purchased a license for its software suite, including the InforSense KDE integrative analytics software, and InforSense Professional Services to build up its workflow-driven bioinformatics computational platform.
Syngenta Bioinformatics plans to deploy InforSense software globally throughout R&D to further its mission of sustainable agriculture through innovative research and technology.
Syngenta will be using InforSense KDE with the bioinformatics application add-on InforSense BioSense and literature analysis application add-on InforSense TextSense, as their Global Bioinformatics Platform for building, managing and deploying analysis workflows.
InforSense’s workflow-driven analytics platform will enable Syngenta to implement a process-based bioinformatics computational platform that automates key analysis workflows with full support for execution automation, resilience and fault tolerance.
The workflows built will leverage in-house applications and web service-enabled federated data integration and analytics for text and bioinformatics analysis.
As a result, Syngenta researchers will benefit from a comprehensive system to enable better decision making as part of their internal agricultural genetics research programs.
"After a thorough and competitive analysis, we selected InforSense software because, right out-of-the-box, it delivers a core of research-relevant, integrative analytic capabilities that give us an information advantage in novel agricultural discovery," said Dr. John Chan, Syngenta’s Head of Global Bioinformatics.
"In addition, InforSense’s Professional Services group demonstrated its ability to help us efficiently customize the solution to fit into our existing data management processes and infrastructure."
"Analytics continues to be one of the only areas within information technology that is delivering significant return-on-investment across business units," said Joseph F. Donahue, InforSense’s Chief Business Officer.
"By applying InforSense KDE and its application-specific add-ons to its crop protection and biotechnology research, Syngenta can turn an information advantage into a competitive differentiator."
"We are pleased they have chosen InforSense KDE and we look forward to working closely with them."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.